Venoms to drugs: translating venom peptides into therapeutics

King, Glenn (2013) Venoms to drugs: translating venom peptides into therapeutics. Australian Biochemist, 44 3: 931-939. doi:10.1080/14789450.2017.1377613

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ336790_fulltext.pdf Full text (open access) application/pdf 405.20KB 0

Author King, Glenn
Title Venoms to drugs: translating venom peptides into therapeutics
Journal name Australian Biochemist   Check publisher's open access policy
ISSN 1478-9450
ISBN 978-1-84973-663-3
Publication date 2013-12-01
Year available 2013
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1080/14789450.2017.1377613
Open Access Status File (Author Post-print)
Volume 44
Issue 3
Start page 931
End page 939
Total pages 4
Publisher The Australian Society for Biochemistry and Molecular Biology (ASBMB)
Language eng
Formatted abstract
Venomous animals have a long history as a source of medical treatments (1). Snake venom, for example, has been used in Ayurvedic medicine since the 7th century BCE to prolong life and treat arthritis and gastrointestinal ailments. Tarantulas are used by indigenous populations of Central and South America to treat ailments ranging from asthma to cancer, while cobra venom has been used since the 1930s to treat conditions as diverse as asthma, polio, multiple sclerosis, rheumatism and pain (2). However, the modern era of venoms-based drug discovery did not begin until the 1970s with the development of the blockbuster  antihypertensive drug captopril, based on a peptide from the venom of the Brazilian viper Bothrops jaracaca (3). Today, many of the major pharmaceutical companies (and most major agrochemical companies) have venom-based drug discovery programs or use venom-derived molecules for target validation (e.g., AstraZeneca, Eli Lilly, Johnson & Johnson and Merck). Moreover, there are now several companies with a focus on venom-derived therapeutics, including Airmid, ReceptoPharm (a subsidiary of Nutra Pharma), Theralpha, VenomeTech, Venomics (a subsidiary of QRxPharma) and Xenome. In this article, I outline recent developments in the venoms-based drug discovery field that might lead to new venom-derived peptide therapeutics.
Keyword Biochemistry
Molecular Biology
Q-Index Code CX
Q-Index Status Provisional Code
Grant ID DP160104025
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collection: Institute for Molecular Bioscience - Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 11 Aug 2014, 23:32:15 EST by Ms Kate Rowe on behalf of Institute for Molecular Bioscience